

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Re: U.S. Patent Application for
Polypeptides Having Dipeptidyl Aminopeptidase Activity And Nucleic Acids
Encoding Same
Applicants: Blinkovsky et al.

Sir:

Express Mail Label No. EV 409172750 US

Date of Deposit: **November 25, 2003**

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Application Data Sheet
4. Information Disclosure Statement
5. Form PTO/SB/08A
6. Statement under 37 CFR 1.808

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and to the address indicated above.

Seleste A. Buriani

(Name of person mailing paper(s) or fee)

Seleste A. Buriani

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Mail Stop Patent Application
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 37 CFR 1.53(b).

INVENTOR(S)		
First Name	Middle Name	Family Name or Surname
1. Alexander	1.	1. Blinkovsky
2. Kim	2.	2. Brown
3. Michael	3. W.	3. Rey
4. Alan		4. Klotz
5. Tony		5. Byun
TITLE OF THE INVENTION		
Polypeptides Having Dipeptidyl Aminopeptidase Activity And Nucleic Acids Encoding Same		

The following application parts are enclosed:

☒ specification 58 pages

☒ Sequence Listing 9 pages

☒ Abstract 1 page

☒ Formal Drawings 4 pages

The filing fee is calculated as follows:

Basic Fee: \$770.00
 Total Claims: 20 - 20 = 0 x 18 = \$0.00
 Independent Claims: 2 - 2 = 0 x 86 = \$0.00
 Total Fee: \$770.00

The benefit of U.S. provisional application no. **60/062,892** filed **October 20, 1997** is claimed under 35 U.S.C. 119(e).

The benefit of U.S. application no. **09/079,592** filed **May 15, 1998** and U.S. application no. **08/857,884** filed **May 16, 1997** is claimed under 35 U.S.C. 120.

An application data sheet is enclosed.

The computer-readable form in this application is identical with that filed in application no. **09/079,592** filed **May 15, 1998**. In accordance with 37 CFR 1.821(e), please use the last computer readable form filed in that application as the computer readable form for the instant application.

The content of the attached Sequence Listing and of the computer readable form filed in the parent application is the same.

The assignee of the present application is:


**Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
US**

Applicants request that the assignee information be included in the published patent application.

Direct all correspondence to Customer Number 25907.

Please charge the required fee, estimated to be \$770, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,



Date: November 25, 2003

Robert L. Starnes, Reg. No. 41,324
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100